Blues TEC Assessment Less Enthusiastic About Carotid Stents Than CMS
This article was originally published in The Gray Sheet
Executive Summary
Existing data on carotid stenting with distal embolic protection fail to demonstrate that the procedure produces better outcomes than surgery, BlueCross BlueShield Association's Technology Evaluation Center concluded Feb. 10
You may also be interested in...
Asymptomatic Carotid Stenting Evaluated By Abbott’s ACT-I Study
Abbott's ACT-I trial is the first randomized clinical trial comparing carotid stenting to endarterectomy surgery in asymptomatic, surgery-eligible patients
CMS Backs Limited Carotid Stent Coverage Expansion, Mulls Criteria For Docs
CMS is soliciting comments on standards and evaluation criteria for physicians and facilities performing carotid artery stenting procedures (CAS)
Cordis Precise, Guidant Acculink Are First “Approvable” Carotid Stents
Johnson & Johnson/Cordis and Guidant are working to satisfy FDA's remaining conditions for approval of their respective Precise and Acculink carotid stent systems, as outlined in recent "approvable" letters